FAQ

Show all

ARAY
The company is traded on the Nasdaq Global Select Market.
Accuray was incorporated in California in 1990 and commenced commercial operations in 1992. Accuray re-incorporated in Delaware in 2007.
Accuray Corporate Headquarters is located at:
1310 Chesapeake Terrace
Sunnyvale, CA 94089

Accuray International Headquarters is located at:
Rte de la Longeraie 9
1110 Morges
Switzerland

Outside of the United States, Accuray currently has regional offices in Morges, Switzerland, Hong Kong, China, Shanghai, China and Tokyo, Japan.
Accuray is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live longer, better lives. Our innovative technologies, the CyberKnife® and TomoTherapy® Systems, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), and adaptive radiation therapy. The CyberKnife Systems and the TomoTherapy Systems have complementary clinical applications, enabling customers to deliver the most precise treatments while minimizing side effects and maximizing patient comfort and care. Each of these systems serves patient populations treated by the same medical specialty, radiation oncology, with advanced capabilities.

CyberKnife Systems are fully robotic systems that deliver SRS and SBRT, and are used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally, without manual user intervention. Treatment with the CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications associated with other treatment options. The latest generation CyberKnife M6 Series System is available with the new InCise Multileaf Collimator (InCise MLC), the world's first multileaf collimator (MLC) to be available on a robotic platform. With the addition of the InCise MLC, clinicians can deliver the same precise radiosurgery treatments they have come to expect with the CyberKnife Systems, while significantly reducing treatment times, for a wider range of tumor types, including larger and different kinds of tumors than were previously treated.

TomoTherapy Systems represent the only radiation therapy platform specifically designed for image-guided intensity-modulated radiation therapy (IG-IMRT). Based on a ring gantry CT scanner platform, the TomoTherapy System provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified direct beam angles. These unique features, combined with daily 3D image guidance, enable physicians to deliver dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients. The TomoTherapy Systems are capable of treating all standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation, while minimizing side effects; and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The latest generation TomoTherapy System is the Radixact® System.

The Radixact System includes the following options: TomoHelical, TomoDirect, and TomoEdge dynamic jaws. The system configuration depends on the options chosen by the customer. Accuray also introduced Onrad® for developing growth markets, such as China, in the third quarter of fiscal 2017. Based on TomoTherapy, Onrad is designed to meet the ease of use and throughput demands of a market segment in which Accuray has not previously competed.

Our Vision and Mission:
We work passionately to create a future without the fear, pain or human suffering of cancer. We pursue this by developing precise, innovative tumor treatment solutions that empower clinicians and help cancer patients live longer, better lives.
Accuray currently markets its systems through a combination of direct sales personnel, distributors and sales agents.
The CyberKnife and TomoTherapy Systems are installed in leading healthcare centers in approximately 50 countries globally.
The CyberKnife and TomoTherapy Systems are FDA approved and CE marked. The CyberKnife System has received FDA 510(k) clearance to provide treatment planning and image-guided robotic radiosurgery for tumors anywhere in the body where radiation treatment is indicated.

In July 1999, Accuray received marketing clearance from the FDA for treatment of tumors in the head, neck and spine. In August 2001, clearance was received from the FDA for treatment of tumors, lesions and conditions anywhere in the body where radiation is indicated. In April 2002, we received 510(k) clearance for the Synchrony Motion Tracking System as an option to the CyberKnife System, intended to enable dynamic image guided stereotactic radiosurgery and precision radiotherapy of lesions, tumors and conditions that move under influence of respiration. In October 2012, we received 510(k) clearance for the InCise MLC with clearance from the FDA on July 1, 2015.

In September 2002, Accuray Incorporated received a CE mark for sale of the CyberKnife System in the Europe Union. The CyberKnife System is also approved to treat an extensive range of indications, in various countries throughout the world.

The TomoTherapy System received U.S. FDA 510(k) clearance, to provide image-guided external beam radiation therapy delivered in a helical delivery pattern, in 2002. The system received further marketing clearance from the FDA in 2005 for stereotactic treatment procedures. In 2008, the system’s TomoDirect™ discrete-angle delivery mode received FDA 510(k) clearance. In June 2016, we received 510(k) clearance for the Radixact Treatment Delivery Platform. We also received 510(k) clearance for our new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.

During 2005, the TomoTherapy System received a CE mark for allowing sale in the European Union. During 2016, the Radixact Treatment Delivery Platform received a CE mark for allowing sale in the European Union as well. Like the CyberKnife System, TomoTherapy and Radixact Systems are cleared for use in various countries throughout the world.
Accuray has approximately 1,000 employees worldwide.
Accuray’s fiscal year ends on June 30.
Please see our Calendar of Events.
Computershare Inc.
(800) 362-7920
(800) 952-9245 (Hearing Impaired)
(201) 680-6578 (Foreign Shareholders)
www.computershare.com/investor Mailing address:
Accuray Incorporated
c/o Computershare Inc.
250 Royall Street
Canton MA 02021
To contact the investor relations department directly, please refer to the Investor Contact section of this site, and to email us, click here.